University of Michigan

Emory University

Rush University Medical Center

Salim Hayek

Jochen Reiser

Arshed A Quyyumi

The disclosure is directed to methods for preventing or treating cardiovascular disease and kidney dysfunction in certain patient populations which involve determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject, and performing various therapeutic interventions based on the suPAR level in the sample.

Use of soluble urokinase plasminogen activator receptor levels to indicate prevention of cardiovascular disease with a statin

Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.

Growing community of inventors

Ann Arbor, MI, United States of America

Salim Hayek